MX2023013616A - Composiciones para el tratamiento de condiciones neurodegenerativas. - Google Patents

Composiciones para el tratamiento de condiciones neurodegenerativas.

Info

Publication number
MX2023013616A
MX2023013616A MX2023013616A MX2023013616A MX2023013616A MX 2023013616 A MX2023013616 A MX 2023013616A MX 2023013616 A MX2023013616 A MX 2023013616A MX 2023013616 A MX2023013616 A MX 2023013616A MX 2023013616 A MX2023013616 A MX 2023013616A
Authority
MX
Mexico
Prior art keywords
treatment
compositions
neurodegenerative conditions
disclosed
solid state
Prior art date
Application number
MX2023013616A
Other languages
English (en)
Spanish (es)
Inventor
Clarence Nathaniel Ahlem
Christopher L Reading
Original Assignee
Biovie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovie Inc filed Critical Biovie Inc
Publication of MX2023013616A publication Critical patent/MX2023013616A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023013616A 2021-05-18 2022-05-02 Composiciones para el tratamiento de condiciones neurodegenerativas. MX2023013616A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163189880P 2021-05-18 2021-05-18
PCT/US2022/027294 WO2022245532A1 (en) 2021-05-18 2022-05-02 Compositions for treatment of neurodegenerative conditions

Publications (1)

Publication Number Publication Date
MX2023013616A true MX2023013616A (es) 2024-01-17

Family

ID=84141848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013616A MX2023013616A (es) 2021-05-18 2022-05-02 Composiciones para el tratamiento de condiciones neurodegenerativas.

Country Status (7)

Country Link
US (1) US20240108636A1 (enExample)
EP (1) EP4341271A4 (enExample)
JP (1) JP2024519079A (enExample)
AU (1) AU2022275684A1 (enExample)
CA (1) CA3218191A1 (enExample)
MX (1) MX2023013616A (enExample)
WO (1) WO2022245532A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054452A1 (en) * 2022-09-06 2024-03-14 Biovie Inc. Methods for the treatment of mild cognitive impairment
WO2025155561A1 (en) * 2024-01-16 2025-07-24 Biovie Inc. Methods of treating long covid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015763A1 (en) * 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
CA2728889C (en) * 2008-04-03 2016-06-14 Harbor Biosciences, Inc. Solid state forms of a pharmaceutical

Also Published As

Publication number Publication date
AU2022275684A1 (en) 2023-11-16
WO2022245532A1 (en) 2022-11-24
EP4341271A1 (en) 2024-03-27
JP2024519079A (ja) 2024-05-08
US20240108636A1 (en) 2024-04-04
EP4341271A4 (en) 2025-04-30
CA3218191A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
UA130338C2 (uk) Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування
BR112022018646A2 (pt) Composto agonista do receptor glp-1, composição farmacêutica compreendendo o mesmo, métodos para preparar o composto e uso do dito composto para prevenir ou tratar uma doença metabólica ou uma doença neurodegenerativa
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
DOP2009000148A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
BRPI0515412A (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI1009381B8 (pt) compostos, composição farmacêutica e uso de compostos e de composição farmacêutica
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
EA200800081A1 (ru) Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты)
BR112012025590A2 (pt) análogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
EA201190234A1 (ru) Новые амидные производные стероидных соединений [3,2-c]пиразолов с глюкокортикоидной активностью
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
MX392132B (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mG1uR2, COMPOSICIONES Y SU USO.
SA522432749B1 (ar) I/alk5 مشتقات بنزيلاميد كمستقبل لمثبطات عامل النمو المتحول-بيتا